


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(10-01)
Approved for use through 12/31/2002. OMB 05-1003
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	08/927,939
Filing Date	September 11, 1997
First Named Inventor	Grainger, David
Group Art Unit	1646
Examiner Name	Murphy, Joseph

Sheet 1 of 2

Attorney Docket No: 1543.001US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
<i>J</i>	US-5,770,609	06/23/1998	Grainger, David J., et al.	514	319	06/07/1995

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ¹
<i>J</i>	WO-00/00821	01/06/2000	Ullman, Edwin F.	G01 N	33/48	
<i>J</i>	WO-92/14455	09/03/1992	Kaplan, , et al.	A61K	31/21	

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>J</i>		BEERS, MARK , et al., "Myeloproliferative Disorders.....", <u>The Merck Manual 7th Edition</u> , (1999), 1474-1476 & 895-902	
<i>J</i>		BUSINCO, L. , et al., "From Alopic Dermatitis to Asthma: The Risk Factors and Preventive Measures", <u>Pediatric Pulmonology, Supplement</u> , 16, (1997), 19-20	
<i>J</i>		ELSON, C. , et al., "Experimental Models of Inflammatory Bowel Disease", <u>Gastroenterology</u> , 109, (1995), pp. 1344-1367	
<i>J</i>		FOX, DANIEL J., "Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo", <u>J. Med. Chem.</u> , 45, (2002), pp. 360-370	
<i>J</i>		FRECKER, M. , et al., "Immunological Associations in Familial and Non-Familial Alzheimer Patients and Their Families", <u>The Canadian Journal of Neurological Sciences</u> , 21, (1994), pp. 112-119	
<i>J</i>		IVACKO, J. , et al., "Hypoxic-Ischemic Injury Induces Monocyte Chemoattractant Protein-1 Expression in Neonatal Rat Brain", <u>Journal of Cerebral Blood Flow and Metabolism</u> , 17, (1997), pp. 759-770	
<i>J</i>		JIN, D. , et al., "Complement 4 Locus II Gene Deletion and DQA1*0301 Gene: Genetic Risk Factors for IgA Nephropathy and Henoch-Schonlein Nephritis", <u>Nephron</u> , 73, (1996), pp. 390-395	
<i>J</i>		KARPUS, W. , et al., "An Important Role for the Chemokine Macrophage Inflammatory Protein-1alpha in the Pathogenesis of the T Cell-Mediated Autoimmune Disease., Experimental Autoimmune Encephalomyelitis", <u>The Journal of Immunology</u> , (1995), pp. 5003-5010	
<i>J</i>		KUNKEL, S. , et al., "The role of chemokines in inflammatory joint disease", <u>Journal of Leukocyte Biology</u> , 59, (1996), pp. 6-12	
<i>J</i>		LUCCHINETTI, C. , et al., "Risk factors for developing multiple sclerosis after childhood optic neuritis", <u>The American Academy of Neurology</u> , 49, (1997), pp. 1413-1418	

EXAMINER

Joseph R. Murphy

DATE CONSIDERED

2.27.05

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 2 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	08/927,939
Filing Date	September 11, 1997
First Named Inventor	Grainger, David
Group Art Unit	1646
Examiner Name	Murphy, Joseph

Attorney Docket No: 1543.001US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>		MARONE, M. , et al., "Influence of body composition on the bone mass of post menopausal women", <u>Sao Paulo Medical Journal</u> , 115(6), (1997),pp. 1580-1588	
<i>[Signature]</i>		MARRA, F. , et al., "Increased Expression of Monocyte Chemotactic Protein-1 during Active Hepatic Fibrogenesis", <u>American Journal of Pathology</u> , 152, (1998),423-430	
<i>[Signature]</i>		MCGEER, P. , et al., "The inflammatory response system of brain: implications for thereapy of Alzheimer and other neurodegenerative diseases", <u>Brain Research Reviews</u> , 21, (1995),pp. 195-218	
<i>[Signature]</i>		NALDI, L. , et al., "Dietary factors and the risk of psoriasis. Results of an Italian case-control study", <u>British Journal of Dermatology</u> , 134, (1996),pp. 101-106	
<i>[Signature]</i>		ONO, K. , et al., "Prevention of Myocardial Reperfusion Injury in Rats by an Antibody against Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1", <u>Laboratory Investigation</u> , 79, (1999),pp. 195-203	
<i>[Signature]</i>		PAUL, W. M., <u>Fundamental Immunology, Fourth Edition</u> , Lippincott-Raven Publ., Philadelphia,(1999),184-185	
<i>[Signature]</i>		PAUL, WILLIAM E., "Fundamental Immunology", <u>3rd Edition</u> , (1993),pp250, 1311-1312.	
<i>[Signature]</i>		REWERS, M. , et al., "Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY)", <u>Diabetologia</u> , 39, (1996),pp. 807-812	
<i>[Signature]</i>		SPENCE, J. , "Advances in atherosclerosis", <u>Bailliere's Clinical Neurology</u> , 4(2), (1995),pp. 191-205	
<i>[Signature]</i>		SUDA, T. , et al., "Modulation of Osteoclast Differentiation by Local Factors", <u>Bone</u> , 17(2), (1995),pp. 87S-91S	
<i>[Signature]</i>		VERMA, M. , et al., "Chemokines in acute anterior uveitis", <u>Current Eye Research</u> , (1997),pp. 1202-1208	
<i>[Signature]</i>		WATANABE, T. , et al., "Atherosclerosis and inflammation Mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA pathway in atherogenesis", <u>International Journal of Cardiology</u> , 66, (1998),pp. S45-S53	

EXAMINER

Joseph D. Murphy

DATE CONSIDERED

2-22-05

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is Applicant to place a check mark here if English language Translation is attached.